Skip to main content

Table 2 Baseline Demographic, Pre-VA ECMO Cardiac Parameters and Adjunct Pre-VA ECMO Treatment of Non-Survivors and Survivors

From: Venoarterial extracorporeal membrane oxygenation for cardiac support in human immunodeficiency virus-positive patients: a case report and review of a multicentre registry

 

Non-Survivors (21)

Survivors (15)

p-value

Demographics

   

 Weight (kg), Median (IQR)

65.8 (56–93)

67 (59–88.6)

0.748

 Age (years), Median (IQR)

48 (29–56)

32 (24–55)

0.194

 Female, n (%)

5 (24)

4 (27)

0.57

 Ethnicity, n (%)

   

  Asian

0 (0)

1 (7)

0.682

  Black

13 (62)

9 (60)

 

  Hispanic

2 (10)

2 (13)

 

  Unknown

1 (5)

0 (0)

 

  White

5 (24)

3 (20)

 

Pre-ECMO Cardiac Parameters

   

 Systolic blood pressure (mmHg), median (IQR)

87.5 (73.5–95.25)

86 (68.5–107)

0.884

 Diastolic blood pressure (mmHg), median (IQR)

53 (47.5–57.25)

58.5 (52.25–69.25)

0.078

Adjunct Pre-VA ECMO Treatment, n (%)

   

 Vasopressor/inotropic drugs*

19 (90)

6 (40)

0.0024

 Cardiopulmonary bypass

2 (10)

2 (13)

1

 Intra-aortic balloon

3 (14)

2 (13)

1

 Nitric oxide

2 (10)

1 (7)

1

 Neuromuscular blockers

6 29)

1 (7)

0.2

 Bicarbonate (Intravenous)

5 (24)

2 (13)

0.67

 Renal Replacement Therapy

4 (19)

1 (7)

0.38

  1. *Vasopressor/inotropic drugs include Adrenaline, Noradrenaline, Vasopressin, Milrinone and Levosimendan and Vasoactive drug not specified.